Evidence map›Paper›PMID 34975191›Full record

ReviewActa clinica Croatica2019

PROSTATE CANCER DIAGNOSIS IN 2019 - CHANGES IN EUROPEAN GUIDELINES AND IMPACT ON DAILY PRACTICE.

Igor Tomašković, Sven Nikles, Miroslav Tomić, Ivan Pezelj, Boris Ružić

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta clinica Croatica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Igor Tomašković1Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb; 2Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; 3Referral Center for Prostate Tumors of the Ministry of Health, Republic of Croatia.
Sven Nikles1Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb; 2Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; 3Referral Center for Prostate Tumors of the Ministry of Health, Republic of Croatia.
Miroslav Tomić1Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb; 2Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; 3Referral Center for Prostate Tumors of the Ministry of Health, Republic of Croatia.
Ivan Pezelj1Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb; 2Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; 3Referral Center for Prostate Tumors of the Ministry of Health, Republic of Croatia.
Boris Ružić1Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb; 2Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia; 3Referral Center for Prostate Tumors of the Ministry of Health, Republic of Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Changes in the diagnostic pathway for prostate cancer advised in the most recent Guidelines of the European Association of Urology bring many endeavors for everyday practice. Availability, costs and radiological expertise are still representing a challenge for the adoption of these guidelines in everyday clinical practice. In this article we discuss the current situation regarding these issues and future options.

Indexed as

GuidelinesMultiparametric Magnetic ResonanceProstate Cancer

Identifiers

PMID34975191
PMCPMC8693554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.